June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
The anti-oxidant effect of vitamin D and homotaurine on progression of early-intermediate age related macular degeneration
Author Affiliations & Notes
  • Flavia Chiosi
    Ophthalmology, Ospedali dei Colli-Monaldi-Napoli, Napoli, Napoli, Italy
  • Emma Minutillo
    Ophthalmology, Ospedali dei Colli-Monaldi-Napoli, Napoli, Napoli, Italy
  • Michele Rinaldi
    Ophthalmology, Università degli studi della Campania Luigi Vanvitelli, Italy
  • Otello Gallo
    Ophthalmology, Ospedali dei Colli-Monaldi-Napoli, Napoli, Napoli, Italy
  • Gianluigi Manzi
    Ophthalmology, Ospedali dei Colli-Monaldi-Napoli, Napoli, Napoli, Italy
  • Footnotes
    Commercial Relationships   Flavia Chiosi, None; Emma Minutillo, None; Michele Rinaldi, None; Otello Gallo, None; Gianluigi Manzi, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1789. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Flavia Chiosi, Emma Minutillo, Michele Rinaldi, Otello Gallo, Gianluigi Manzi; The anti-oxidant effect of vitamin D and homotaurine on progression of early-intermediate age related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1789.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Drusen are hallmarks of age-related macular degeneration (AMD). In literature it has been evidenced that amyloid-beta (Aβ), the peptide associated with neurodegenerative events in Alzheimer’s disease, is an important constituent of drusen.
Homotaurine and vitamin D have been shown to bind Aβ and inhibit its induced neurotoxicity in retinal cellular assays.
We decided to perform a prospective, double blind , placebo-controlled study to test the efficacy of vitamin D and homotaurine in patients affected by early-intermediate AMD.

Methods : Fifty-three patients affected by early-intermediate AMD were enrolled in the study and randomized (2:1) to receive 1 tablet/day of a nutritional supplement containing a mixture of vitamin D 50 μg (1000%), homotaurine 50 mg plus complete AREDS 2 formula or placebo for 12 months.
AMD progression was assessed by optical coherence tomography changes in drusen size (primary outcome), retinography, Amsler test, visual function quality test (NEI-VFQ), best corrected visual acuity (BCVA) for distance and near. Main inclusion criteria were: diagnosis of early-intermediate AMD according to AREDS classification; presence of small-medium drusen (≥ 63 μm, < 125 μm) in macular zone; BCVA for distance ≥ 20/32 ETDRS charts; BCVA for near ≥ 20/32 Snellen Decimal (LogMar 0.2) at the MNREAD chart. Main exclusion criteria were: myopia > 3 diopter; other macular disorders; cataract and eye surgery 3 months prior to enrollment study.
Differences in the two arms were evaluated using chi-square test or Fisher’s exact test.

Results : Fifty patients completed the follow-up at 12 months. An AMD progression was observed in 2.5 % of patients of the treated arm and in 19.4 % of patients in the placebo arm (p = 0.05, Fisher’s exact test). No significant difference was found in BCVA between the placebo (51.6±6.3 letters) and treated arm (53.4 ± 5.6 letters), while a statistically significant reduction ( p= 0.05) in drusen size was observed in treated group (mean reduction 6.5 μm from baseline) versus placebo (0 μm from baseline).

Conclusions : Our results are consistent with the hypothesis that vitamin D and homotaurine, along with AREDS 2 formulation, can further reduce the progression of AMD in patients affected by early-intermediate stage disease, decreasing the presence of Aβ in drusen.

This is a 2020 ARVO Annual Meeting abstract.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×